Determination of Lymphotoxin-Alpha Levels in Patients with Psoriatic Arthritis Undergoing Etanercept Treatment

2012 ◽  
Vol 32 (6) ◽  
pp. 277-279 ◽  
Author(s):  
Giuseppe Murdaca ◽  
Barbara Maria Colombo ◽  
Paola Contini ◽  
Francesco Puppo
Keyword(s):  
Psoriatic Arthritis ◽  
Etanercept Treatment ◽  
Lymphotoxin Alpha

Composite scores in psoriatic arthritis

2018 ◽  
Author(s):  
Philip S. Helliwell
Keyword(s):  
Psoriatic Arthritis ◽  
Disease Activity ◽  
Statistical Power ◽  
Assessment Tools ◽  
Composite Score ◽  
Low Disease Activity ◽  
Feasible Alternative ◽  
The Individual ◽  
Composite Scores

Composite scores are assessment tools that combine a number of separate evaluations into one score. The composite score generally has more statistical power than the individual items, is more responsive, and has a greater effect size. A composite score allows synthesis of several elements into one score which can then, if psychometrically appropriate, allow the determination of disease activity (both low and high) cut-offs, and response criteria. The topics discussed in this chapter are the development and use of composite scores to assess disease activity in psoriatic arthritis: their history and development, use in practice, psychometric characteristics, and relative merits. Although there is no overall consensus on which measure to use, either in clinical trials or in the clinic, there appears to be agreement that remission should be the ideal target of treatment, with minimal/low disease activity a feasible alternative.

Etanercept treatment patterns in managed-care patients with psoriasis or psoriatic arthritis

2010 ◽  
Vol 13 (2) ◽  
pp. 228-235 ◽  
Author(s):  
Sarah Thayer ◽  
Crystal Watson ◽  
Rui Song ◽  
Denise R. Globe ◽  
David J. Harrison
Keyword(s):  
Psoriatic Arthritis ◽  
Managed Care ◽  
Treatment Patterns ◽  
Etanercept Treatment

scholarly journals Effectiveness and Safety of Etanercept in Patients with Psoriatic Arthritis in a Canadian Clinical Practice Setting: The REPArE Trial

2011 ◽  
Vol 38 (7) ◽  
pp. 1355-1362 ◽  
Author(s):  
DAFNA D. GLADMAN ◽  
CLAIRE BOMBARDIER ◽  
CARTER THORNE ◽  
BOULOS HARAOUI ◽  
MAJED KHRAISHI ◽  
...  
Keyword(s):  
Clinical Practice ◽  
Psoriatic Arthritis ◽  
Assessment Tool ◽  
Clinical Symptoms ◽  
Health Assessment ◽  
Work Productivity ◽  
Severity Index ◽  
Continuous Treatment ◽  
Joint Disease ◽  
Etanercept Treatment

Objective.To describe the longterm effectiveness and safety of etanercept in Canadian patients with psoriatic arthritis (PsA), treated over 24 months in clinical practice.Methods.Patients with active PsA (≥ 3 tender and ≥ 3 swollen joints) were recruited from 22 centers. Etanercept was administered at 50 mg/week subcutaneously. In addition to clinical assessment of skin and joint disease, conducted at baseline and at Months 6, 12, 18, and 24, regular patient interviews were conducted by telephone. Patient responses related to health status, disability, and work productivity were scored using the patient global assessment tool, the Health Assessment Questionnaire (HAQ), the Health and Labour Questionnaire (HLQ), and the Fatigue Severity Scale.Results.Out of 110 patients, 71 (65%) maintained etanercept treatment through the end of our study. All clinical measures of disease severity, including joint tenderness/pain, joint swelling, and Psoriasis Area and Severity Index score, improved significantly between baseline and Month 6 of etanercept treatment and remained constant thereafter. By the end of our study, 79% of patients achieved a Psoriatic Arthritis Response Criteria response, and 56% of patients achieved a 0.5-point improvement on HAQ, indicating clinically significant improvement in disability; 14% of patients finished our study free of disability (HAQ = 0). Patients’ work productivity and fatigue improved significantly in parallel with these clinical and functional improvements.Conclusion.Continuous treatment with etanercept over 2 years in a clinical setting improved clinical symptoms of PsA while reducing fatigue, improving work productivity, and ameliorating or eliminating disability.

scholarly journals Patient-reported Outcomes in a Randomized Trial of Etanercept in Psoriatic Arthritis

2010 ◽  
Vol 37 (6) ◽  
pp. 1221-1227 ◽  
Author(s):  
PHILIP J. MEASE ◽  
J. MICHAEL WOOLLEY ◽  
AMITABH SINGH ◽  
WAYNE TSUJI ◽  
MELEANA DUNN ◽  
...  
Keyword(s):  
Psoriatic Arthritis ◽  
Pain Assessment ◽  
Patient Reported Outcomes ◽  
Short Form ◽  
Health Assessment ◽  
Open Label ◽  
Double Blind ◽  
Etanercept Treatment ◽  
Sf 36 ◽  
Patient Reported

Objective.To evaluate the effects of etanercept treatment on patient-reported outcomes (PRO) in patients with psoriatic arthritis (PsA).Methods.A 24-week double-blind comparison to placebo was followed by a 48-week open-label phase in which all eligible patients received etanercept. PRO were measured using the Stanford Health Assessment Questionnaire Disability Index (HAQ-DI), the Medical Outcomes Study Short-Form (SF-36), the EQ-5D visual analog scale (VAS), and the American College of Rheumatology (ACR) patient pain assessment.Results.Beginning at Week 4 and continuing through Week 24 of double-blind treatment, patients treated with etanercept had significantly higher mean percentage improvement in HAQ-DI relative to baseline than patients given placebo (53.6% vs 6.4% at Week 24; p < 0.001). After 48 weeks of open-label treatment with etanercept, the mean percentage change from study baseline was 52.8% for the original etanercept group and 46.9% for the original placebo group, with 41.2% of patients overall achieving a HAQ-DI of 0. Mean changes relative to baseline for SF-36 physical component summary scores, EQ-5D VAS, and ACR pain assessment were also significant in the double-blind period for etanercept compared with placebo (p < 0.001 for all 3 measures). Patients taking placebo achieved similar improvements once they began treatment with etanercept in the open-label period.Conclusion.Patients with PsA treated with etanercept reported significant improvements in physical function that were almost 10 times the improvement seen with placebo and were maintained for up to 2 years. Almost half of patients treated with etanercept reported no disability by the end of the study.

scholarly journals Etanercept treatment of psoriatic arthritis: Safety, efficacy, and effect on disease progression

2004 ◽  
Vol 50 (7) ◽  
pp. 2264-2272 ◽  
Author(s):  
Philip J. Mease ◽  
Alan J. Kivitz ◽  
Francis X. Burch ◽  
Evan L. Siegel ◽  
Stanley B. Cohen ◽  
...  
Keyword(s):  
Psoriatic Arthritis ◽  
Disease Progression ◽  
Etanercept Treatment
Sign in / Sign up

Export Citation Format

Share Document